Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN N versus HUMULIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN N versus HUMULIN R.
HUMULIN N vs HUMULIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin isophane (NPH) is an intermediate-acting insulin that lowers blood glucose by promoting peripheral glucose uptake, especially in muscle and adipose tissue, and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways.
Human insulin is identical to endogenous insulin. It binds to insulin receptors on target cells, activates tyrosine kinase signaling, and promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis and glycogenolysis.
0.5-1 unit/kg/day subcutaneously, divided into 2 doses (morning and evening).
Subcutaneous: 0.2-0.6 units/kg/day divided into 2-3 doses, individualized. Intravenous: Insulin infusion protocols for hyperglycemia.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours (subcutaneous); longer in renal impairment.
Terminal elimination half-life: 0.5-1 hour (intravenous); prolonged in renal impairment (up to 3-4 hours).
Renal: 60-80% as intact insulin; hepatic and renal clearance; negligible biliary/fecal elimination.
Primarily renal (>90% as unchanged drug after degradation), with minor biliary/fecal elimination (<10%).
Category C
Category C
Human Insulin
Human Insulin